UK: Implications Of The Greek Crisis On Pharmaceutical Reference Pricing

Last Updated: 21 July 2015
Article by Karen Taylor and Elizabeth Hampson

Most Read Contributor in UK, August 2017

Over the past few weeks, national and international media coverage has been rife with speculation about whether Greece will retain the Euro. At the time of posting this blog, Eurozone leaders have agreed to the conditions for Greece to seek a third bailout and the Greek government agreed to accept the bailout conditions - but several European Union (EU) members, including Germany, must ratify the deal in their parliaments before it can proceed.1 Whatever happens over the next few weeks there is still some way to go and uncertainty about Greece's financial future. This week's blog does not attempt to predict the outcome but examines a key issue challenging the pharma industry, the impact of the current economic turmoil and continued uncertainty on pharmaceutical pricing.

Like many others international businesses, pharma companies have been struggling under austerity in Greece for many years. In May 2015 Reuters reported that Greek hospitals and the state-run insurer (in full EOPYY) owe international pharma companies more than $1.2 billion.2 While earlier debts, incurred between 2010 and 2012, were eventually repaid, some pharma companies received their payment in government bonds that were subsequently written down in value. Furthermore, pharma companies report that they haven't been paid by state hospitals or the government's public health insurer since December 2014.3

Although Greece represents less than one per cent of global drug sales, its impact on the global pharmaceutical market, should it leave the Euro, could be significant due to the impact of international reference pricing (IRP). IRP also known as external reference pricing, is a policy method employed by Governments to try and control the prices of in-patent pharmaceuticals. All countries use a range of policies to control expenditure on drugs, both in and out-of patent. These policies include statutory pricing, price-volume agreements, profit controls, negotiations, rebates and clawbacks and IRP as discussed in the Centre's report impact of Austerity on European Pharmaceutical policy and pricing.4

IRP is one of the most common methods deployed in Europe, with most European countries using some form of external referencing. Indeed, a European Commission study in 2013, comprising 31 European countries (28 EU member states, Switzerland, Norway and Iceland) found that 29 countries applied ERP (exception being the UK and Sweden). The majority of the countries (23 out of 31) use ERP as the main systematic criterion when setting the price of a new drug. The most referenced countries are France (19), followed by the UK and Germany (17). The least referenced countries are Croatia entered in the EU in July 2013 (5) and non-EU MS: Switzerland (2), Iceland (3) and Norway (6).

A group of between five to 20 countries tend to be referenced directly and further countries referenced indirectly. For example the UK is referenced by 17 of the EU member states and indirectly referenced by many of the others, meaning a headline price cut in the UK could result in price cuts in many of these markets, even those not directly referencing the UK.5

There are a number of challenges to IRP as a policy tool including: country selection; price setting mechanisms; frequency of rebalancing; and exchange rate fluctuations. For example, in June 2014, the European Federation of Pharmaceutical Industries and Associations (EPFIA) stated that IRP is "fundamentally flawed from an economical point of view". EFPIA believe that countries should only reference those countries with comparable Gross Domestic Product (GDP) per capita (adjusted for purchasing power parity) and comparable healthcare funding systems and that the lowest prices in the basket should not be used to set prices.6

Thirteen countries directly reference Greek pharma prices.7 The pharma industry is concerned that, were Greece to exit the euro, its new currency would devalue and, affect pharma pricing in countries referencing Greek prices. For example, if Greece were to leave the Euro and adopt its own currency (the Drachma) some experts predict a devaluation of 40-60 per cent of its currency relative to the Euro.8 This would mean that Greek pharma prices in Euro terms would be halved in value.

Earnings on imported pharmaceuticals would drop sharply, slashing in-market profitability for pharma companies. There would be knock on effects on any countries referencing Greece who would have this cheaper basket of drugs within their reference price basket. Not all countries reference the lowest prices in the basket, but the cost of Greek pharmaceuticals would also lower the basket average for those referencing the average price. This could represent a boon for countries struggling to contain pharma spend and another hit to a pharma industry trying to improve its business model. EPFIA has also warned the European Commission that availability of cheaper drugs in Greece could result in parallel trade, with Greeks selling these drugs at higher prices in neighboring EU countries, leading to supply issues in Greece.9

As always with the business of pharmaceuticals there are ethical dilemmas that need to be considered alongside any commercial decisions. Unlike many other businesses, pharma companies cannot just withdraw products that are essential to patients simply for reasons of profitability.

Under a Grexit scenario pharma companies have few options. One option being to halt the supply of higher priced drugs, but only if there is a therapeutic substitute available, the other is to get agreement from other European governments to exclude Greece from their reference price baskets. However, the impact of any such actions may be limited as Grexit would still have a negative impact on pharma's profitability in the short to medium term. While current events look to have provided a temporary reprieve to Grexit risk, concerns over the sustainability of the European IRP system remain, suggesting the time is ripe to have an informed international debate about pharmaceutical pricing mechanisms.

Footnotes (14 July) and (16 July)








The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.